TAG interviewed 100 institutions and documented the top 40 investors in TB R&D in 2005. Results highlighted in the report showed that new tools including diagnostics, drugs and vaccines received combined funding of $206 million in 2005 -- diagnostics, $16…
A Talk With Gavin Churchyard By Mark Harrington Professor Gavin Churchyard is the director of the Aurum Institute for Health Research, which provides health care services to many mining companies in South Africa but is also an independent health research…
By Theo Smart In all the news and hype about the cases of extensively drug resistant tuberculosis (XDR-TB) in KwaZulu Natal, South Africa, there has been surprisingly little discussion about how and where many of the people acquired the XDR-TB…
TB, HIV and Viral Hepatitis By Tracy Swan Disturbing reports of overlapping TB, HIV, and viral hepatitis epidemics emerged at the 2005 International AIDS Society Conference. In the newly independent states of Eastern Europe and Central Asia, HIV incidence continues…
A Crisis for People Living With HIV/AIDS Worldwide By Javid Syed Globally, TB is the most common infection and a leading cause of death among people living with HIV. Despite being curable, TB accounts for two million deaths each year…
Mixed Results (and Lots of Diarrhea) for the Tipranavir Studies; Plus Salvage Study Designs for JNJ/Tibotec's PI and Non-Nuke By Rob Camp and Mike Barr "Boosting to Break the Bank" Boehringer Ingelheim filed its new drug approval applications for tipranavir…
Treatment Advocates Strategize At TAG's 2nd Annual International TB/HIV Workshop Activists From 31 Countries Building on the success of the First International TB/HIV Community Education and Mobilization Workshop, held in conjunction with the 33rd International Union Against Tuberculosis and Lung…
by Rob Camp January: starts as new TAG's Antiviral Project Director. Rob and Mark to Houston for ATAC structure meeting to develop stronger national coalition, then to D.C. for Federal AIDS Policy Partnership meeting. Talk of coming assault on Medicaid…
January: HIV vaccine papers in Nature by Merck's Emilio Emini, Harvard's Dan Barouch. February: First ATAC (AIDS Treatment Activist Conference) teach-in, Seattle (seventy people attend), followed by ATAC/BMS meeting and Retrovirus conference. NIH cancels large phase III canarypox HIV vaccine…
January: TAG's Gregg Gonsalves becomes GMHC Director of Treatment Policy. Completion of STI Workshop 2000 report. FDA hearing on salvage therapy trial design. Merck meeting on promising DNA/adenovirus HIV vaccine. TAG mobilizes 600 signatures on global letter to Glaxo decrying…